(Q54631030)

1 June 2018

title

Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. (English)

1 reference

1 June 2018

1 reference

C Algire

1

1 reference

1 June 2018

L Amrein

2

1 reference

1 June 2018

M Bazile

3

1 reference

1 June 2018

S David

4

1 reference

1 June 2018

M Zakikhani

5

1 reference

1 June 2018

M Pollak

6

1 reference

1 June 2018

language of work or name

English

0 references

publication date

22 November 2010

1 reference

1 June 2018

published in

Oncogene

1 reference

1 June 2018

volume

30

1 reference

1 June 2018

issue

10

1 reference

1 June 2018

page(s)

1174-1182

1 reference

1 June 2018

https://scigraph.springernature.com/pub.10.1038/onc.2010.483

exact match

0 references

cites work

Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

A colorimetric assay for the measurement of D-glucose consumption by cultured cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

Long-term metformin use is associated with decreased risk of breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

Chemoprevention meets glucose control

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

Metformin and reduced risk of cancer in diabetic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

Neither LKB1 nor AMPK are the direct targets of metformin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

Metformin Suppresses Colorectal Aberrant Crypt Foci in a Short-term Clinical Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

LKB1 modulates lung cancer differentiation and metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

AMP-activated protein kinase induces a p53-dependent metabolic checkpoint

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

Tumours with PI3K activation are resistant to dietary restriction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

Tumor cell metabolism: cancer's Achilles' heel

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

Diabetes mellitus and risk of breast cancer: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

Diabetes mellitus and risk of colorectal cancer: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

Metformin induces unique biological and molecular responses in triple negative breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

Metformin Prevents Tobacco Carcinogen–Induced Lung Tumorigenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

Insulin and insulin-like growth factor signalling in neoplasia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

Do cancer cells care if their host is hungry?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

Metformin and other biguanides in oncology: advancing the research agenda

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

The LKB1-AMPK pathway: metabolism and growth control in tumour suppression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

Targeting metabolic transformation for cancer therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

Metformin suppresses intestinal polyp growth in ApcMin/+ mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

Somatic LKB1 mutations promote cervical cancer progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2010.483

31 March 2020

Identifiers

DOI

10.1038/ONC.2010.483

1 reference

1 June 2018

1 reference

1 June 2018